Cargando…
Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies
The vast spectrum of clinical features of COVID-19 keeps challenging scientists and clinicians. Low resistance to infection might result in long-term viral persistence, but the underlying mechanisms remain unclear. Here, we studied the immune response of immunocompetent COVID-19 patients with prolon...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300054/ https://www.ncbi.nlm.nih.gov/pubmed/37529320 http://dx.doi.org/10.1016/j.isci.2023.107219 |
_version_ | 1785064503234265088 |
---|---|
author | Montes-Cobos, Elena Bastos, Victoria C. Monteiro, Clarice de Freitas, João C.R. Fernandes, Heiny D.P. Constancio, Clarice S. Rodrigues, Danielle A.S. Gama, Andreza M.D.S. Vidal, Vinicius M. Alves, Leticia S. Zalcberg-Renault, Laura de Lira, Guilherme S. Ota, Victor A. Caloba, Carolina Conde, Luciana Leitão, Isabela C. Tanuri, Amilcar Ferreira, Orlando D.C. Pereira, Renata M. Vale, André M. Castiñeiras, Terezinha M. Kaiserlian, Dominique Echevarria-Lima, Juliana Bozza, Marcelo T. |
author_facet | Montes-Cobos, Elena Bastos, Victoria C. Monteiro, Clarice de Freitas, João C.R. Fernandes, Heiny D.P. Constancio, Clarice S. Rodrigues, Danielle A.S. Gama, Andreza M.D.S. Vidal, Vinicius M. Alves, Leticia S. Zalcberg-Renault, Laura de Lira, Guilherme S. Ota, Victor A. Caloba, Carolina Conde, Luciana Leitão, Isabela C. Tanuri, Amilcar Ferreira, Orlando D.C. Pereira, Renata M. Vale, André M. Castiñeiras, Terezinha M. Kaiserlian, Dominique Echevarria-Lima, Juliana Bozza, Marcelo T. |
author_sort | Montes-Cobos, Elena |
collection | PubMed |
description | The vast spectrum of clinical features of COVID-19 keeps challenging scientists and clinicians. Low resistance to infection might result in long-term viral persistence, but the underlying mechanisms remain unclear. Here, we studied the immune response of immunocompetent COVID-19 patients with prolonged SARS-CoV-2 infection by immunophenotyping, cytokine and serological analysis. Despite viral loads and symptoms comparable to regular mildly symptomatic patients, long-term carriers displayed weaker systemic IFN-I responses and fewer circulating pDCs and NK cells at disease onset. Type 1 cytokines remained low, while type-3 cytokines were in turn enhanced. Of interest, we observed no defects in antigen-specific cytotoxic T cell responses, and circulating antibodies displayed higher affinity against different variants of SARS-CoV-2 Spike protein in these patients. The identification of distinct immune responses in long-term carriers adds up to our understanding of essential host protective mechanisms to ensure tissue damage control despite prolonged viral infection. |
format | Online Article Text |
id | pubmed-10300054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103000542023-06-28 Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies Montes-Cobos, Elena Bastos, Victoria C. Monteiro, Clarice de Freitas, João C.R. Fernandes, Heiny D.P. Constancio, Clarice S. Rodrigues, Danielle A.S. Gama, Andreza M.D.S. Vidal, Vinicius M. Alves, Leticia S. Zalcberg-Renault, Laura de Lira, Guilherme S. Ota, Victor A. Caloba, Carolina Conde, Luciana Leitão, Isabela C. Tanuri, Amilcar Ferreira, Orlando D.C. Pereira, Renata M. Vale, André M. Castiñeiras, Terezinha M. Kaiserlian, Dominique Echevarria-Lima, Juliana Bozza, Marcelo T. iScience Article The vast spectrum of clinical features of COVID-19 keeps challenging scientists and clinicians. Low resistance to infection might result in long-term viral persistence, but the underlying mechanisms remain unclear. Here, we studied the immune response of immunocompetent COVID-19 patients with prolonged SARS-CoV-2 infection by immunophenotyping, cytokine and serological analysis. Despite viral loads and symptoms comparable to regular mildly symptomatic patients, long-term carriers displayed weaker systemic IFN-I responses and fewer circulating pDCs and NK cells at disease onset. Type 1 cytokines remained low, while type-3 cytokines were in turn enhanced. Of interest, we observed no defects in antigen-specific cytotoxic T cell responses, and circulating antibodies displayed higher affinity against different variants of SARS-CoV-2 Spike protein in these patients. The identification of distinct immune responses in long-term carriers adds up to our understanding of essential host protective mechanisms to ensure tissue damage control despite prolonged viral infection. Elsevier 2023-06-28 /pmc/articles/PMC10300054/ /pubmed/37529320 http://dx.doi.org/10.1016/j.isci.2023.107219 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Montes-Cobos, Elena Bastos, Victoria C. Monteiro, Clarice de Freitas, João C.R. Fernandes, Heiny D.P. Constancio, Clarice S. Rodrigues, Danielle A.S. Gama, Andreza M.D.S. Vidal, Vinicius M. Alves, Leticia S. Zalcberg-Renault, Laura de Lira, Guilherme S. Ota, Victor A. Caloba, Carolina Conde, Luciana Leitão, Isabela C. Tanuri, Amilcar Ferreira, Orlando D.C. Pereira, Renata M. Vale, André M. Castiñeiras, Terezinha M. Kaiserlian, Dominique Echevarria-Lima, Juliana Bozza, Marcelo T. Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies |
title | Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies |
title_full | Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies |
title_fullStr | Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies |
title_full_unstemmed | Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies |
title_short | Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies |
title_sort | oligosymptomatic long-term carriers of sars-cov-2 display impaired innate resistance but increased high-affinity anti-spike antibodies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300054/ https://www.ncbi.nlm.nih.gov/pubmed/37529320 http://dx.doi.org/10.1016/j.isci.2023.107219 |
work_keys_str_mv | AT montescoboselena oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT bastosvictoriac oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT monteiroclarice oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT defreitasjoaocr oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT fernandesheinydp oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT constancioclarices oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT rodriguesdanielleas oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT gamaandrezamds oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT vidalviniciusm oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT alvesleticias oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT zalcbergrenaultlaura oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT deliraguilhermes oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT otavictora oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT calobacarolina oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT condeluciana oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT leitaoisabelac oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT tanuriamilcar oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT ferreiraorlandodc oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT pereirarenatam oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT valeandrem oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT castineirasterezinham oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT kaiserliandominique oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT echevarrialimajuliana oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies AT bozzamarcelot oligosymptomaticlongtermcarriersofsarscov2displayimpairedinnateresistancebutincreasedhighaffinityantispikeantibodies |